Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Results of the CYP-GUIDES randomized controlled trial: Total cohort and primary endpoints.

Contemporary clinical trials - 1 Feb 2020

Ruaño Gualberto, Robinson Saskia, Holford Theodore, Mehendru Raveen, Baker Seth, Tortora Joseph, Goethe John W

Abstract excerpt

CYP-GUIDES (Cytochrome Psychotropic Genotyping Under Investigation for Decision Support) is a randomized controlled trial (RCT) comparing 2 outcomes in hospitalized patients with major depressive disorder (MDD) treated according to the patient's CYP2D6 genotype and functional status versus standard psychotropic therapy. The primary outcome was hospital Length of Stay (LOS) and the secondary outcome was the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Depressive Disorder, Major

Share to Length of Stay

Share to Research Design

Share to Socioeconomic Factors

Share to Young Adult

Source

Identifiers

PMID: 31838256
DOI: 10.1016/j.cct.2019.105910

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Results of the CYP-GUIDES randomized controlled trial: Total cohort and primary endpoints.PMID 31838256Read ↗

Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder - a retrospective cohort studySemantic proximity Read ↗

[Clinical interest of CYP2D6 genotyping to treat depression in practice].Semantic proximity Read ↗

Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system.Semantic proximity Read ↗

Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).Semantic proximity Read ↗

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.Semantic proximity Read ↗

Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder a retrospective cohort study CYP2D6 genotype and antidepressant response.Semantic proximity Read ↗

A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 e CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder.Semantic proximity Read ↗

Integrating Genetic Variants and Expression Profiles of Pharmacogenes in Treatment- Resistant DepressionSemantic proximity Read ↗

Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test.Semantic proximity Read ↗

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responsesSemantic proximity Read ↗

Nine-gene pharmacogenomics profile service: The Mayo Clinic experience.Semantic proximity Read ↗

Pharmacogenetics testing for poor response to antidepressants: a transnosographic case seriesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.